208 related articles for article (PubMed ID: 8237943)
1. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
3. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
[TBL] [Abstract][Full Text] [Related]
5. The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis.
Kinnby B; Matsson L; Lecander I
Scand J Dent Res; 1994 Dec; 102(6):334-41. PubMed ID: 7871356
[TBL] [Abstract][Full Text] [Related]
6. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Ganesh S; Sier CF; Griffioen G; Vloedgraven HJ; de Boer A; Welvaart K; van de Velde CJ; van Krieken JH; Verheijen JH; Lamers CB
Cancer Res; 1994 Aug; 54(15):4065-71. PubMed ID: 8033138
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Gris JC; Schved JF; Marty-Double C; Mauboussin JM; Balmes P
Chest; 1993 Jul; 104(1):8-13. PubMed ID: 7686838
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits.
Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z
Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381
[TBL] [Abstract][Full Text] [Related]
13. The expression of plasminogen activator system in a rat model of periodontal wound healing.
Xiao Y; Li H; Bunn C; Bartold PM
J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
15. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
17. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
18. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
20. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
